Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
sulfasalazine
|
| gptkbp:brand |
gptkb:Azulfidine_EN-tabs
|
| gptkbp:clinicalTrials |
Phase III
|
| gptkbp:commonName |
1 to 2 g per day
|
| gptkbp:contraindication |
porphyria
sulfa allergy |
| gptkbp:date |
1950
|
| gptkbp:dosageForm |
500 mg
1000 mg |
| gptkbp:drugInterdiction |
sulfonamide
anti-rheumatic |
| gptkbp:endOfLife |
7 to 12 hours
|
| gptkbp:firstAwarded |
rheumatoid arthritis
mild to moderate ulcerative colitis |
| gptkbp:formulation |
tablet
suspension |
| gptkbp:gestationPeriod |
B
|
| gptkbp:healthcare |
important
take with food stay hydrated regular follow-up appointments report any rash immediately |
| https://www.w3.org/2000/01/rdf-schema#label |
Azulfidine
|
| gptkbp:interactsWith |
warfarin
methotrexate azathioprine cyclosporine |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:nutritionalValue |
hepatic
|
| gptkbp:operates_in |
A07EC01
|
| gptkbp:researchFocus |
combination therapies
long-term outcomes improving efficacy biomarkers for response reducing side effects |
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
monitor blood counts
avoid in breastfeeding avoid in pregnancy monitor liver function |
| gptkbp:sideEffect |
headache
nausea diarrhea rash |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
anti-inflammatory
|
| gptkbp:usedFor |
rheumatoid arthritis
ulcerative colitis |
| gptkbp:waterManagement |
urine
|